Lumos ASX Share Price: LDX Quote, Market Cap and News
If you have searched for the Lumos ASX share price and come away with two different market caps, you are not imagining things. Reuters via Stockopedia (wire news reporting) reported that Lumos Diagnostics (ASX:LDX) shares fell as much as 22.6% to A$0.065 on 27 Oct 2026, and this piece dates each price and valuation so the conflicting figures make sense.
Ticker: ASX:LDX · Last reported price (27 Oct 2026 snapshot): AU$0.06 · Market cap (27 Oct 2026 snapshot): AU$22.46M (lower-tier source) · Session move (11 Nov 2026): unconfirmed in cited sources
Quick snapshot
- Lumos trades on the ASX under ASX:LDX (Lumos Diagnostics company investor page) (Yahoo Finance Australia (daily price history))
- Shares fell as much as 22.6% to A$0.065 on 27 Oct 2026, per Reuters via Stockopedia (wire news reporting) (Yahoo Finance Australia (daily price history))
- Yahoo’s history records a 13 Nov 2026 close of 0.0700 (Yahoo Finance Australia (daily price history))
- 52-week low: $0.055 at the Financial Times (price tearsheet) versus $0.06 reportedly at Intelligent Investor (share price data)
- Market cap: AU$22.46M on 27 Oct 2026 (Australian Stock Report, independent stock site) versus 59.29M on 10 Nov 2026 with no currency stated (Yahoo Finance Australia (key statistics))
- The 8.57% gain on 11 Nov 2026 has no match in cited sources, and Motley Fool Australia (daily price history) shows a $0.07 close that day
- FY26 full-year results released 26 Aug 2026, with the price at release at $0.100 (Intelligent Investor (announcements feed))
- Quarterly cash flow report released 27 Oct 2026, the same day as the selloff (Intelligent Investor announcements feed) (Intelligent Investor (announcements feed))
- FebriDx expansion announced 9 Nov 2026 at a release price of $0.060 (Intelligent Investor announcements feed) (Intelligent Investor (announcements feed))
- No price forecast or analyst target appears in the cited sources
- No next results date is given in the cited sources
- Check the Intelligent Investor announcements feed for any newly dated release
Seven rows, one pattern: every price and valuation figure changes with its snapshot date, and the two market caps are not stated on a common basis.
| Label | Value |
|---|---|
| Ticker | ASX:LDX |
| Last reported price (27 Oct 2026 snapshot) | AU$0.06 (Financial Times historical data lists a 0.064 close) |
| Session move (11 Nov 2026) | Unconfirmed in cited sources |
| 52-week low (29 Oct 2026, per FT) | $0.055 |
| 52-week high | A$0.33 |
| Market cap (27 Oct 2026 snapshot) | AU$22.46M (lower-tier source) |
| Market cap (10 Nov 2026 snapshot) | 59.29M, currency not stated |
What is the current share price of Lumos Diagnostics Holdings (ASX:LDX)?
The latest close in the cited data is A$0.07 on 13 Nov 2026. Yahoo Finance Australia (daily price history) records 0.0700 that day, on volume of 697,280, with a day range of 0.0690 to 0.0740.
Intelligent Investor’s quote page shows a share price of $0.070 at 16:40 on 13 Nov 2026, with a last close of $0.071 (Intelligent Investor share price data).
Is there a reliable Lumos asx share price forecast?
- No cited source gives a price forecast, analyst target or rating.
- Every figure in the research is a dated quote or a past session close.
The implication: readers should treat these quotes as a record of past trading, not a projection of where the stock goes next.
Why do price figures differ between sources?
- Timing: Financial Times (historical price tables) lists a 27 Oct 2026 close of 0.064, while the snapshot records AU$0.06 for the same day.
- Lows: the 52-week low is $0.055 at Simply Wall St (company analytics platform), while Intelligent Investor reportedly gives $0.06.
A quote without a timestamp is half a number. Two prices a few cents apart can both be accurate if they were captured on different days.
The implication: date-stamp every price before comparing providers, because most disputes over a figure are really disputes over the day it describes.
What is the market capitalization of Lumos Diagnostics?
Reported valuation depends heavily on the snapshot date. Australian Stock Report (independent stock site) puts market capitalization at AU$22.46M on 27 Oct 2026, while Yahoo Finance Australia (key statistics) shows 59.29M on 10 Nov 2026 with no currency stated.
StockAnalysis (market data aggregator) lists a 10 Nov 2026 market cap of 68.02M and 971.67M shares outstanding.
Why do reported market caps differ?
- Market capitalization equals share price multiplied by shares on issue.
- At StockAnalysis’s share count of 971.67M, a 0.0600 price gives about AU$58.3M, which matches the AUD 58.30 million it lists for a 30 Oct 2026 close (StockAnalysis (statistics page)).
- The AU$22.46M figure implies only about 374 million shares at a 0.06 price, well below the 971.67M shares StockAnalysis lists.
A market cap quoted without a date describes one price on one day, not the company’s value today. The AU$22.46M figure does not reconcile with the share count, so it should not be read on its own.
The implication: use the 10 Nov 2026 and 30 Oct 2026 figures as the reconcilable pair, and treat the AU$22.46M number as an outlier until a primary record confirms it.
What does LDX ASX do?
Smallcaps (UK small-cap site) describes Lumos Diagnostics as an Australia-based company specialising in point-of-care diagnostic test technology for healthcare professionals. The company’s investor page confirms that Lumos is a publicly traded company listed on the Australian Securities Exchange under ticker ASX:LDX (Lumos Diagnostics company investor page).
What is point-of-care testing?
- Point-of-care tests run near the patient, not only in a central laboratory.
- FebriDx is a Lumos point-of-care test, and its adoption expansion at WellStreet locations was announced on 9 Nov 2026 (Intelligent Investor announcements feed).
The implication: the business depends on tests reaching clinics and bedside settings, which makes adoption announcements the most direct signal of demand.
Why are Lumos Diagnostics shares moving?
The cited sources record price moves but do not establish a confirmed cause for most of them. The clearest explanation comes from wire reporting on 27 Oct 2026: Reuters via Stockopedia (wire news reporting) reported that shares fell as much as 22.6% to A$0.065, their lowest since July 2025, after quarterly revenue of $2 million, down 39% from $3.4 million a year earlier.
The same day, the Intelligent Investor announcements feed lists a quarterly cash flow report released at 9:59AM.
What did the 11 Nov 2026 session show?
- Motley Fool Australia (daily price history) lists a $0.07 close on 11 Nov 2026 on volume of 1,114,005.
- The same source lists a 9 Nov 2026 close of $0.07, up 16.67% on volume of 8,439,691.
- No cited source confirms an 8.57% session gain to AU$0.076.
A 16.67% gain on more than eight million shares, less than two weeks after a 22.6% intraday fall, points to heavy trading rather than a settled price. The research does not link that rise to any single event.
The implication: the price moved in the same weeks as company announcements, but the record stops short of proving that any announcement drove the move.
Who is the CEO of Lumos Diagnostics?
None of the cited sources names the chief executive, so this article cannot confirm who leads Lumos Diagnostics. One search question refers to “Surlux Diagnostic Ltd”, a name that matches no cited source.
Where can the CEO appointment be verified?
- Official ASX company announcements are the verifiable record for leadership changes, and each carries a release date and time.
- The Intelligent Investor announcements feed lists Lumos releases by date and time, which makes it a usable index.
The catch: a name on a quote page is not a substitute for a dated announcement, so check the ASX release before quoting any executive.
Key dates on the record
- : Yahoo Finance Australia (daily price history) records a close of 0.3200 and an intraday high of 0.3250, the peak in the cited data.
- : FY26 Full Year Results announcement released at 9:44AM, with the price at release of $0.100 (Intelligent Investor announcements feed).
- : Shares fall as much as 22.6% to A$0.065 (Reuters via Stockopedia, wire news reporting); the quarterly cash flow report is released at 9:59AM.
- : Financial Times (price tearsheet) dates a 52-week low of 0.055.
- : Intelligent Investor cites a 52-week low of $0.06, which it reportedly records.
- : FebriDx expansion announced at 8:31AM at $0.060, with the price at $0.070 when listed (Intelligent Investor announcements feed).
- : Latest close in the cited data at A$0.07 (Yahoo Finance Australia daily price history).
Why this matters: the price fell from $0.100 at the August results to a 0.055 low by late October, and the record holds no single dated event that explains the recovery to about $0.07 by 13 Nov 2026.
Confirmed facts and open questions
Confirmed facts
- Lumos trades on the ASX under ASX:LDX (Lumos Diagnostics company investor page).
- Shares fell as much as 22.6% to A$0.065 on 27 Oct 2026 (Reuters via Stockopedia, wire news reporting).
- Yahoo’s history records a 13 Nov 2026 close of 0.0700 (Yahoo Finance Australia daily price history).
What’s unclear
- The 52-week low: $0.055 in most sources, but $0.06 reportedly at Intelligent Investor.
- Market cap: AU$22.46M versus 59.29M, with differing dates and no currency stated on one figure.
- The 8.57% session gain has no cited match.
- The cause of the 27 Oct 2026 drop and the 9 Nov 2026 rise is not established in the sources.
- The CEO’s name appears in no cited source.
Why this matters: the open items are the ones that drive investment decisions, so the confirmed list is the only one to build on.
What the reporting says
“Shares of Lumos Diagnostics LDX.AX fall as much as 22.6% to A$0.065, marking their lowest level since July 2025.”
Swetha Lakshmi, Reuters reporter via Stockopedia (wire news)
“The diagnostic tests maker reports quarterly revenue of $2 million, down 39% from $3.4 million a year earlier.”
Swetha Lakshmi, Reuters reporter via Stockopedia (wire news)
Lumos Diagnostics is a publicly-traded company listed on the Australian Securities Exchange under ticker ASX:LDX.
Lumos Diagnostics (company investor page)
The implication: the Reuters account is the most specific dated description of the drop in the research, while the company’s own page confirms only the listing and ticker.
What this means for investors
The Lumos price story is less about one number than about which number a reader picks up. An investor who skips the date stamp on each quote will read a 0.06 figure and a 0.07 figure as two verdicts on the company, when they may simply be two different trading days.
Related reading: Brent crude oil price today: benchmark, history and supply
finance.yahoo.com, au.finance.yahoo.com, investing.com, smallcaps.co.uk
Frequently asked questions
Where can I check the live LDX share price?
The research contains dated quotes rather than a live feed. The most recent close in the cited data is A$0.07 on 13 Nov 2026, per Yahoo Finance Australia (daily price history).
What exchange is Lumos Diagnostics listed on?
Lumos is listed on the Australian Securities Exchange under ticker ASX:LDX, according to the Lumos Diagnostics investor page (company listing record).
What ticker symbol does Lumos Diagnostics use on the ASX?
The ticker is LDX, written as ASX:LDX. Yahoo’s data pages use LDX.AX (Yahoo Finance Australia key statistics).
How much can the LDX share price move in one session?
In the cited data, shares fell as much as 22.6% intraday on 27 Oct 2026 (Reuters via Stockopedia, wire news reporting), and closed up 16.67% on 9 Nov 2026 (Motley Fool Australia daily price history).
How should readers date a share price snapshot?
Record the provider, the exact time and the currency. Intelligent Investor’s quote, for example, is stamped 16:40 on 13 Nov 2026 (Intelligent Investor share price data). Financial Times historical data lists a 27 Oct 2026 close of 0.064, which explains why AU$0.06 and 0.064 can both appear for the same day.
Does a low share price mean a company is cheap?
No. A low price says little about value on its own. In the same period, quarterly revenue of $2 million was down 39% from a year earlier (Reuters via Stockopedia, wire news reporting), which is the figure investors should weigh alongside price.
More related posts
Forearm Tattoos for Men: Designs, Meanings & Placement
New Zealand Fraudsters List: Notable Cases & Convictions
Best Apps for Goal Setting in 2026: Top Picks Reviewed
Rainbow Mountain Scenic Reserve: Walk Length, Cost, and Tips
Jinweide Beef Noodle Wellington Menu: Dishes, Prices and Gaps
Toyota RAV4 for Sale NZ: Prices, Best Years & Reviews
When Is the Next Blood Moon NZ – Exact Date, Times, Tips
